Neoplasms

Digestive System Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Stomach Neoplasms

Hypertrophy

Precancerous Conditions

Gastritis

Gastritis, Hypertrophic

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Gastroenteritis

Stomach Cancer

Menetrier Disease

Antineoplastic Agents

All Drugs and Chemicals

Cetuximab

Antineoplastic Agents, Immunological

Cetuximab lV weekly at an initial loading dose of 400 ml/m2, followed by three weekly maintenance doses of 250 mg/m2. Four infusions of C225 will be defined as a course of therapy.

Robert J. Coffey, MD

RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

PURPOSE: This clinical trial is studying how well cetuximab works in treating patients with Ménétrier disease at high risk of developing stomach cancer.

OBJECTIVES:

* Evaluate clinical and biochemical parameter response in patients with Ménétrier disease at high risk of developing gastric cancer treated with cetuximab.

OUTLINE: This is a non-randomized study.

Patients receive cetuximab IV on days 1, 8, 15, and 22. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.

Patients complete a quality of life questionnaire at baseline and during week 4.

PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.

Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer

Treatment of Ménétrier's Disease With EGF Receptor Blockade

National Cancer Institute (NCI)

Vanderbilt University

Asst Professor, Otolaryngology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer	NCT00477880	Gastric Cancer Precancerous Co...	Cetuximab	18 Years - 80 Years	Vanderbilt University Medical Center
Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer	NCT00477880	Gastric Cancer Precancerous Co...	Cetuximab	18 Years - 80 Years	Vanderbilt University Medical Center

Spots Global Cancer Trial Database for giant hypertrophic gastritis